article thumbnail

Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More

Xconomy

—Amgen (NASDAQ: AMGN ), of Thousand Oaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen. . TheStreet.com has more here.

Avalon 40